Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma

Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V. Maus, Ashley Turka, Lyh Ping Lam, Richard A. Morgan, Kevin Friedman, Monica Massaro, Julie Wang, Greg Russotti, Zhihong Yang, Timothy Campbell, Kristen Hege, Fabio PetroccaM. Travis Quigley, Nikhil Munshi, James N. Kochenderfer

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

BACKGROUND Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS In this phase 1 study involving patients with relapsed or refractory multiple myeloma, we administered bb2121 as a single infusion at doses of 50×10 6 , 150×10 6 , 450×10 6 , or 800×10 6 CAR-positive (CAR+) T cells in the dose-escalation phase and 150×10 6 to 450×10 6 CAR+ T cells in the expansion phase. Patients had received at least three previous lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or were refractory to both drug classes. The primary end point was safety. RESULTS Results for the first 33 consecutive patients who received a bb2121 infusion are reported. The data-cutoff date was 6.2 months after the last infusion date. Hematologic toxic effects were the most common events of grade 3 or higher, including neutropenia (in 85% of the patients), leukopenia (in 58%), anemia (in 45%), and thrombocytopenia (in 45%). A total of 25 patients (76%) had cytokine release syndrome, which was of grade 1 or 2 in 23 patients (70%) and grade 3 in 2 patients (6%). Neurologic toxic effects occurred in 14 patients (42%) and were of grade 1 or 2 in 13 patients (39%). One patient (3%) had a reversible grade 4 neurologic toxic effect. The objective response rate was 85%, including 15 patients (45%) with complete responses. Six of the 15 patients who had a complete response have had a relapse. The median progression-free survival was 11.8 months (95% confidence interval, 6.2 to 17.8). All 16 patients who had a response (partial response or better) and who could be evaluated for minimal residual disease (MRD) had MRD-negative status (≤10 −4 nucleated cells). CAR T-cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion. CONCLUSIONS We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented.

Original languageEnglish (US)
Pages (from-to)1726-1737
Number of pages12
JournalNew England Journal of Medicine
Volume380
Issue number18
DOIs
StatePublished - May 2 2019

Fingerprint

B-Cell Maturation Antigen
Antigen Receptors
Cell- and Tissue-Based Therapy
Multiple Myeloma
T-Cell Antigen Receptor
Poisons
Residual Neoplasm
Nervous System

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., ... Kochenderfer, J. N. (2019). Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. New England Journal of Medicine, 380(18), 1726-1737. https://doi.org/10.1056/NEJMoa1817226

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. / Raje, Noopur; Berdeja, Jesus; Lin, Yi; Siegel, David; Jagannath, Sundar; Madduri, Deepu; Liedtke, Michaela; Rosenblatt, Jacalyn; Maus, Marcela V.; Turka, Ashley; Lam, Lyh Ping; Morgan, Richard A.; Friedman, Kevin; Massaro, Monica; Wang, Julie; Russotti, Greg; Yang, Zhihong; Campbell, Timothy; Hege, Kristen; Petrocca, Fabio; Travis Quigley, M.; Munshi, Nikhil; Kochenderfer, James N.

In: New England Journal of Medicine, Vol. 380, No. 18, 02.05.2019, p. 1726-1737.

Research output: Contribution to journalArticle

Raje, N, Berdeja, J, Lin, Y, Siegel, D, Jagannath, S, Madduri, D, Liedtke, M, Rosenblatt, J, Maus, MV, Turka, A, Lam, LP, Morgan, RA, Friedman, K, Massaro, M, Wang, J, Russotti, G, Yang, Z, Campbell, T, Hege, K, Petrocca, F, Travis Quigley, M, Munshi, N & Kochenderfer, JN 2019, 'Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma', New England Journal of Medicine, vol. 380, no. 18, pp. 1726-1737. https://doi.org/10.1056/NEJMoa1817226
Raje, Noopur ; Berdeja, Jesus ; Lin, Yi ; Siegel, David ; Jagannath, Sundar ; Madduri, Deepu ; Liedtke, Michaela ; Rosenblatt, Jacalyn ; Maus, Marcela V. ; Turka, Ashley ; Lam, Lyh Ping ; Morgan, Richard A. ; Friedman, Kevin ; Massaro, Monica ; Wang, Julie ; Russotti, Greg ; Yang, Zhihong ; Campbell, Timothy ; Hege, Kristen ; Petrocca, Fabio ; Travis Quigley, M. ; Munshi, Nikhil ; Kochenderfer, James N. / Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. In: New England Journal of Medicine. 2019 ; Vol. 380, No. 18. pp. 1726-1737.
@article{c265e627598d4f4b80468e26c239f618,
title = "Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma",
abstract = "BACKGROUND Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS In this phase 1 study involving patients with relapsed or refractory multiple myeloma, we administered bb2121 as a single infusion at doses of 50×10 6 , 150×10 6 , 450×10 6 , or 800×10 6 CAR-positive (CAR+) T cells in the dose-escalation phase and 150×10 6 to 450×10 6 CAR+ T cells in the expansion phase. Patients had received at least three previous lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or were refractory to both drug classes. The primary end point was safety. RESULTS Results for the first 33 consecutive patients who received a bb2121 infusion are reported. The data-cutoff date was 6.2 months after the last infusion date. Hematologic toxic effects were the most common events of grade 3 or higher, including neutropenia (in 85{\%} of the patients), leukopenia (in 58{\%}), anemia (in 45{\%}), and thrombocytopenia (in 45{\%}). A total of 25 patients (76{\%}) had cytokine release syndrome, which was of grade 1 or 2 in 23 patients (70{\%}) and grade 3 in 2 patients (6{\%}). Neurologic toxic effects occurred in 14 patients (42{\%}) and were of grade 1 or 2 in 13 patients (39{\%}). One patient (3{\%}) had a reversible grade 4 neurologic toxic effect. The objective response rate was 85{\%}, including 15 patients (45{\%}) with complete responses. Six of the 15 patients who had a complete response have had a relapse. The median progression-free survival was 11.8 months (95{\%} confidence interval, 6.2 to 17.8). All 16 patients who had a response (partial response or better) and who could be evaluated for minimal residual disease (MRD) had MRD-negative status (≤10 −4 nucleated cells). CAR T-cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion. CONCLUSIONS We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented.",
author = "Noopur Raje and Jesus Berdeja and Yi Lin and David Siegel and Sundar Jagannath and Deepu Madduri and Michaela Liedtke and Jacalyn Rosenblatt and Maus, {Marcela V.} and Ashley Turka and Lam, {Lyh Ping} and Morgan, {Richard A.} and Kevin Friedman and Monica Massaro and Julie Wang and Greg Russotti and Zhihong Yang and Timothy Campbell and Kristen Hege and Fabio Petrocca and {Travis Quigley}, M. and Nikhil Munshi and Kochenderfer, {James N.}",
year = "2019",
month = "5",
day = "2",
doi = "10.1056/NEJMoa1817226",
language = "English (US)",
volume = "380",
pages = "1726--1737",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "18",

}

TY - JOUR

T1 - Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma

AU - Raje, Noopur

AU - Berdeja, Jesus

AU - Lin, Yi

AU - Siegel, David

AU - Jagannath, Sundar

AU - Madduri, Deepu

AU - Liedtke, Michaela

AU - Rosenblatt, Jacalyn

AU - Maus, Marcela V.

AU - Turka, Ashley

AU - Lam, Lyh Ping

AU - Morgan, Richard A.

AU - Friedman, Kevin

AU - Massaro, Monica

AU - Wang, Julie

AU - Russotti, Greg

AU - Yang, Zhihong

AU - Campbell, Timothy

AU - Hege, Kristen

AU - Petrocca, Fabio

AU - Travis Quigley, M.

AU - Munshi, Nikhil

AU - Kochenderfer, James N.

PY - 2019/5/2

Y1 - 2019/5/2

N2 - BACKGROUND Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS In this phase 1 study involving patients with relapsed or refractory multiple myeloma, we administered bb2121 as a single infusion at doses of 50×10 6 , 150×10 6 , 450×10 6 , or 800×10 6 CAR-positive (CAR+) T cells in the dose-escalation phase and 150×10 6 to 450×10 6 CAR+ T cells in the expansion phase. Patients had received at least three previous lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or were refractory to both drug classes. The primary end point was safety. RESULTS Results for the first 33 consecutive patients who received a bb2121 infusion are reported. The data-cutoff date was 6.2 months after the last infusion date. Hematologic toxic effects were the most common events of grade 3 or higher, including neutropenia (in 85% of the patients), leukopenia (in 58%), anemia (in 45%), and thrombocytopenia (in 45%). A total of 25 patients (76%) had cytokine release syndrome, which was of grade 1 or 2 in 23 patients (70%) and grade 3 in 2 patients (6%). Neurologic toxic effects occurred in 14 patients (42%) and were of grade 1 or 2 in 13 patients (39%). One patient (3%) had a reversible grade 4 neurologic toxic effect. The objective response rate was 85%, including 15 patients (45%) with complete responses. Six of the 15 patients who had a complete response have had a relapse. The median progression-free survival was 11.8 months (95% confidence interval, 6.2 to 17.8). All 16 patients who had a response (partial response or better) and who could be evaluated for minimal residual disease (MRD) had MRD-negative status (≤10 −4 nucleated cells). CAR T-cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion. CONCLUSIONS We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented.

AB - BACKGROUND Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma. METHODS In this phase 1 study involving patients with relapsed or refractory multiple myeloma, we administered bb2121 as a single infusion at doses of 50×10 6 , 150×10 6 , 450×10 6 , or 800×10 6 CAR-positive (CAR+) T cells in the dose-escalation phase and 150×10 6 to 450×10 6 CAR+ T cells in the expansion phase. Patients had received at least three previous lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or were refractory to both drug classes. The primary end point was safety. RESULTS Results for the first 33 consecutive patients who received a bb2121 infusion are reported. The data-cutoff date was 6.2 months after the last infusion date. Hematologic toxic effects were the most common events of grade 3 or higher, including neutropenia (in 85% of the patients), leukopenia (in 58%), anemia (in 45%), and thrombocytopenia (in 45%). A total of 25 patients (76%) had cytokine release syndrome, which was of grade 1 or 2 in 23 patients (70%) and grade 3 in 2 patients (6%). Neurologic toxic effects occurred in 14 patients (42%) and were of grade 1 or 2 in 13 patients (39%). One patient (3%) had a reversible grade 4 neurologic toxic effect. The objective response rate was 85%, including 15 patients (45%) with complete responses. Six of the 15 patients who had a complete response have had a relapse. The median progression-free survival was 11.8 months (95% confidence interval, 6.2 to 17.8). All 16 patients who had a response (partial response or better) and who could be evaluated for minimal residual disease (MRD) had MRD-negative status (≤10 −4 nucleated cells). CAR T-cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion. CONCLUSIONS We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented.

UR - http://www.scopus.com/inward/record.url?scp=85065137503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065137503&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1817226

DO - 10.1056/NEJMoa1817226

M3 - Article

C2 - 31042825

AN - SCOPUS:85065137503

VL - 380

SP - 1726

EP - 1737

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 18

ER -